adalimumab-aaty (Yuflyma) vs infliximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
infliximab · Remicade
Marketed by Johnson & Johnson
NCT00094458 · Phase 3 · completed
This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).
Next expected readout: November 2026 · NCT05906576 (registry estimate)
Reported efficacy
Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) (met)
Result source: NCT00094458
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | infliximab |
|---|---|---|
| Clinical remission (induction) | —Not reported | 47.3% vs 34.1%vs Azathioprine + PlaceboNCT000944585 other results
|
| Endoscopic response (induction) | —Not reported | —Not posted · NCT00004941 |
| Clinical remission (maintenance) | —Not reported | 66% vs 54.7%vs Azathioprine + PlaceboNCT000944587 other results
|
| Endoscopic response (maintenance) | —Not reported | —Not posted · NCT00004941 |
Clinical remission (induction)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- 47.3% vs 34.1%vs Azathioprine + PlaceboNCT00094458
5 other results
- 59.8% vs 34.1% NCT00094458
- 49.1% vs 27.6% NCT00094458
- 52.1% vs 27.6% NCT00094458
- 32.5% vs 17.6% NCT00094458
- 36.7% vs 17.6% NCT00094458
Endoscopic response (induction)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- —Not posted · NCT00004941
Clinical remission (maintenance)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- 66% vs 54.7%vs Azathioprine + PlaceboNCT00094458
7 other results
- 74.1% vs 54.7% NCT00094458
- 72.2% vs 58.7% NCT00094458
- 73.1% vs 58.7% NCT00094458
- 66% vs 61.3% NCT00094458
- 69.4% vs 61.3% NCT00094458
- 47.9% vs 31.8% NCT00094458
- 60.4% vs 31.8% NCT00094458
Endoscopic response (maintenance)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- —Not posted · NCT00004941
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-aaty (Yuflyma): no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-aaty (Yuflyma): 0 of 4 rows · infliximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | infliximab |
|---|---|
| Dropout rate | 28.4%Infliximab + Azathioprinea NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results34.3%Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 0% NCT01580670 · Phase 3 · monotherapy 13.3% NCT00805766 · Phase 3 · monotherapy 18.2% NCT00688636 · Phase 4 · registry result, not featured evidence 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 16.6%Infliximab + Azathioprinea NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results11.8%Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 — NCT01580670 · Phase 3 · monotherapy 2.2% NCT00805766 · Phase 3 · monotherapy 18.2% NCT00688636 · Phase 4 · registry result, not featured evidence 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Serious AEs | —Infliximab + Azathioprinea NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results—Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 14%W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 16%W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 1.9%W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 15.5%W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 14.3% NCT01580670 · Phase 3 · monotherapy — NCT00805766 · Phase 3 · monotherapy 9.1% NCT00688636 · Phase 4 · registry result, not featured evidence 0% NCT00791557 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a nausea 21.8% abdominal pain 13.4% fatigue 13.4% NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 6 more resultsabdominal pain 9.3% nasopharyngitis 8.3% crohn's disease 5.6% NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 double stranded dna antibody positive 50% gastroenteritis 21.4% headache 21.4% NCT01580670 · Phase 3 · monotherapy infusion reaction 18.2% (placebo 7.7%) abcess 9.1% (placebo 7.7%) bronchitis 9.1% (placebo 0%) NCT00688636 · Phase 4 · registry result, not featured evidence bone marrow suppression 50% infection 50% infusion reaction 50% NCT00791557 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
infliximab
show 3 more results
show 1 more result
show 15 more results
show 15 more results
show 9 more results
show 9 more results
show 13 more results
show 13 more results
show 13 more results
+ 6 further endpoints in the CSV export.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
infliximab · Remicade
Marketed by Johnson & Johnson
NCT01585155 · Phase 3 · completed
No randomization, no blinding (masking: NONE), no control arm, single-group design with only 21 patients — this defaults to 'weak' per the design rules regardless of the favorable-looking remission percentages.
Next expected readout: December 2026 · NCT06839820 (registry estimate)
Reported efficacy
Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
Result source: NCT01585155
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | infliximab |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Trial running · NCT06614387 |
| Clinical remission (maintenance) | —Not reported | —Trial running · NCT06614387 |
| Clinical response (induction) | —Not reported | —Trial running · NCT06614387 |
| Endoscopic improvement (induction) | —Not reported | —Trial running · NCT06614387 |
| Corticosteroid-free remission (maintenance) | —Not reported | —Trial running · NCT06614387 |
Clinical remission (induction)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- —Trial running · NCT06614387
Clinical remission (maintenance)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- —Trial running · NCT06614387
Clinical response (induction)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- —Trial running · NCT06614387
Endoscopic improvement (induction)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- —Trial running · NCT06614387
Corticosteroid-free remission (maintenance)
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- —Trial running · NCT06614387
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-aaty (Yuflyma): no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-aaty (Yuflyma): 0 of 4 rows · infliximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | infliximab |
|---|---|
| Dropout rate | 23.8%a NCT01585155 · Phase 3 · monotherapy show 3 more results47.8%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 18.2%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 4.8%a NCT01585155 · Phase 3 · monotherapy show 3 more results26.1%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.6%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Serious AEs | 14.3%a NCT01585155 · Phase 3 · monotherapy show 3 more results21.7%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 18.2%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0% NCT00791557 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a double stranded dna antibody positive 57.1% nasopharyngitis 33.3% acne 9.5% NCT01585155 · Phase 3 · monotherapy show 3 more results5 mg/kg every 12 weeks colitis ulcerative 65.2% upper respiratory tract infection 26.1% pain 17.4% NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5 mg/kg every 8 weeks colitis ulcerative 31.8% upper respiratory tract infection 31.8% fever 27.3% NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 bone marrow suppression 50% infection 50% infusion reaction 50% NCT00791557 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
infliximab
+ 31 further endpoints in the CSV export.
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
infliximab · Remicade
Marketed by Johnson & Johnson
NCT00106847 · Phase 3 · completed
This randomized, double-blind trial enrolled 683 patients and measured the proportion achieving at least 75% skin clearance (PASI 75), a standard psoriasis efficacy measure, at week 10. Infliximab produced clearance rates of 70-75% depending on dose, compared with 2% on placebo, a highly statistically significant difference.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: June 2030 · NCT07352566 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved a Greater Than Equal to 75 Percent Response in Psoriasis Area and Severity Index (PASI) (Week 10): PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001) (met)
Result source: NCT01177800
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | infliximab |
|---|---|---|
| PASI 75 | —Not posted · NCT05495568 | 81% vs 2.2%+78.8 vs placeboNCT01177800 |
| PASI 90 | —Not posted · NCT05495568 | —Not posted · NCT00106847 |
| PASI 100 | —Not posted · NCT05495568 | —Not posted · NCT00106847 |
| sPGA 0/1 | —Not posted · NCT05495568 | 88.1% vs 6.7%+81.4 vs placeboNCT011778001 other result
|
| DLQI, change | —Not posted · NCT05495568 | -8 vs -1.5−6.5 vs placeboNCT01177800 |
PASI 75
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- infliximab
- 81% vs 2.2%+78.8 vs placeboNCT01177800
PASI 90
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- infliximab
- —Not posted · NCT00106847
PASI 100
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- infliximab
- —Not posted · NCT00106847
sPGA 0/1
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- infliximab
- 88.1% vs 6.7%+81.4 vs placeboNCT01177800
1 other result
- 0.8% vs 0.4% NCT00251641
DLQI, change
- adalimumab-aaty (Yuflyma)
- —Not posted · NCT05495568
- infliximab
- -8 vs -1.5−6.5 vs placeboNCT01177800
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-aaty (Yuflyma): no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-aaty (Yuflyma): 0 of 4 rows · infliximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | infliximab |
|---|---|
| Dropout rate | 11.9%a NCT01177800 · Phase 3 show 17 more results18.4%5 mg/kg NCT00686595 · Phase 4 · registry result, not featured evidence —TA-650(Dose Escalation Period)Over NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Plaq NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Pust NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Entire Evaluation Period)Pl NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Entire Evaluation Period)Ps NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Overall NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Plaque P NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Psoriati NCT01680159 · Phase 3 · registry result, not featured evidence 16.7% NCT00527072 · Phase 3 · registry result, not featured evidence 0% NCT00629772 · Phase 3 · registry result, not featured evidence 18.9%5 mg/kg NCT00687401 · Phase 3 · registry result, not featured evidence 26.1%5 mg/kg NCT00686686 · Phase 3 · registry result, not featured evidence 17.2% NCT00251641 · Phase 3 · registry result, not featured evidence 13.6%5 mg/kg NCT00687362 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 10.7%a NCT01177800 · Phase 3 show 17 more results7.9%5 mg/kg NCT00686595 · Phase 4 · registry result, not featured evidence —TA-650(Dose Escalation Period)Over NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Plaq NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Pust NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Entire Evaluation Period)Pl NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Entire Evaluation Period)Ps NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Overall NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Plaque P NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Psoriati NCT01680159 · Phase 3 · registry result, not featured evidence 6% NCT00527072 · Phase 3 · registry result, not featured evidence — NCT00629772 · Phase 3 · registry result, not featured evidence 3.8%5 mg/kg NCT00687401 · Phase 3 · registry result, not featured evidence 8.7%5 mg/kg NCT00686686 · Phase 3 · registry result, not featured evidence 12.3% NCT00251641 · Phase 3 · registry result, not featured evidence —5 mg/kg NCT00687362 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.8%a NCT01177800 · Phase 3 show 17 more results18.4%5 mg/kg NCT00686595 · Phase 4 · registry result, not featured evidence 9.8%TA-650(Dose Escalation Period)Over NCT01680159 · Phase 3 · registry result, not featured evidence 12.9%TA-650(Dose Escalation Period)Plaq NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence 14.3%TA-650(Dose Escalation Period)Pust NCT01680159 · Phase 3 · registry result, not featured evidence 11.1%TA-650(Entire Evaluation Period)Pl NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Entire Evaluation Period)Ps NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Normal Dose Period)Overall NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Normal Dose Period)Plaque P NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Normal Dose Period)Psoriati NCT01680159 · Phase 3 · registry result, not featured evidence 3.7% NCT00527072 · Phase 3 · registry result, not featured evidence 16.7% NCT00629772 · Phase 3 · registry result, not featured evidence 1.3%5 mg/kg NCT00687401 · Phase 3 · registry result, not featured evidence 17.4%5 mg/kg NCT00686686 · Phase 3 · registry result, not featured evidence 6.8% NCT00251641 · Phase 3 · registry result, not featured evidence 0%5 mg/kg NCT00687362 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a upper respiratory tract infection 14.3% (placebo 11.1%) antinuclear antibody positive 11.9% (placebo 6.7%) asthenia 11.9% (placebo 11.1%) NCT01177800 · Phase 3 show 17 more results5 mg/kg pruritus 10.5% rhinitis 7.9% blood triglycerides increased 5.3% NCT00686595 · Phase 4 · registry result, not featured evidence double stranded dna antibody positive 49% nasopharyngitis 27.5% headache 7.8% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 58.1% nasopharyngitis 22.6% dyspnoea 9.7% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 25% alanine aminotransferase increased 12.5% arthralgia 12.5% NCT01680159 · Phase 3 · registry result, not featured evidence nasopharyngitis 60% double stranded dna antibody positive 40% alanine aminotransferase increased 20% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 42.9% nasopharyngitis 42.9% chapped lips 14.3% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 69.4% nasopharyngitis 22.2% dyspnoea 8.3% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 60% alanine aminotransferase increased 10% arthralgia 10% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 34.8% nasopharyngitis 8.7% psoriasis 4.3% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 33.3% nasopharyngitis 11.1% aspartate aminotransferase increased 2.8% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 40% erythema 10% feeling hot 10% NCT01680159 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 9.8% arthralgia 8.8% headache 6.5% NCT00527072 · Phase 3 · registry result, not featured evidence common cold 25% (placebo 25%) fatigue 16.7% (placebo 8.3%) joint pain in hand 16.7% (placebo 0%) NCT00629772 · Phase 3 · registry result, not featured evidence 5 mg/kg hepatic enzyme increased 13% asthenia 8.7% folliculitis 8.7% NCT00686686 · Phase 3 · registry result, not featured evidence nasopharyngitis 18.3% infusion related reaction 10.8% headache 10.2% NCT00251641 · Phase 3 · registry result, not featured evidence 5 mg/kg pyrexia 18.2% cough 13.6% oropharyngeal pain 13.6% NCT00687362 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
infliximab
show 1 more result
show 2 more results
show 3 more results
show 4 more results
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 2 more results
+ 8 further endpoints in the CSV export.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
NCT03789292 · Phase 3 · completed
This randomized, double-blind Phase 3 equivalence trial compared CT-P17 (Yuflyma) with EU-approved Humira in 648 adults with active rheumatoid arthritis. The primary endpoint was ACR20 response at week 24, and equivalence required the confidence interval of the difference to fall inside predefined margins. ACR20 response was 82.7% in both groups; the 95% CI (-5.94 to 5.94) and the 90% CI (-4.98 to 4.98) were inside the margins, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Kay 2021).
Reported efficacy
American College of Rheumatology(ACR)20 Response Rate at Week 24.: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). (met)
Result source: NCT03789292
infliximab · Remicade
Marketed by Johnson & Johnson
NCT00269867 · Phase 3 · completed
This randomised, double-blind, placebo-controlled trial in 428 patients with rheumatoid arthritis (ATTRACT) reported ACR20 responses of 50-58% across the infliximab plus methotrexate regimens against 20% on placebo plus methotrexate at week 30 (P<0.001 for each regimen), on a validated measure of disease activity.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | infliximab |
|---|---|---|
| ACR20 | 82.7% vs 82.7%vs HumiraNCT03789292 | 56.6% vs 53%vs Remicade-USNCT0299080651 other results
|
| ACR50 | —Not reported | 30.8% vs 32.7%vs Remicade USNCT0299080650 other results
|
| ACR70 | —Not reported | 17.2% vs 18.5%vs Remicade USNCT0299080649 other results
|
| DAS28-CRP remission | —Not reported | —Not posted · NCT01217086 |
| HAQ-DI, change | —Not reported | -0.5 vs -0.5vs Remicade USNCT0299080624 other results
|
| Modified Sharp score, change | —Not reported | —Not posted · NCT01217086 |
ACR20
- adalimumab-aaty (Yuflyma)
- 82.7% vs 82.7%vs HumiraNCT03789292
- infliximab
- 56.6% vs 53%vs Remicade-USNCT02990806
51 other results
- 52% vs 46.4% NCT02990806
- 55.3% vs 46.4% NCT02990806
- 52.4% vs 47.2% NCT02990806
- 54.3% vs 47.2% NCT02990806
- 52.4% vs 46.4% NCT02990806
- 56.9% vs 46.4% NCT02990806
- 54.2% vs 48.8% NCT02990806
- 55.8% vs 48.8% NCT02990806
- 52.4% vs 47.2% NCT02990806
- 49.2% vs 47.2% NCT02990806
- 54.6% vs 47.2% NCT02990806
- 50.8% vs 47.2% NCT02990806
- 54.2% vs 50% NCT02990806
- 59.9% vs 50% NCT02990806
- 56.4% vs 50.8% NCT02990806
- 59.4% vs 50.8% NCT02990806
- 51.1% vs 48% NCT02990806
- 51.3% vs 48% NCT02990806
- 53.7% vs 50% NCT02990806
- 54.3% vs 50% NCT02990806
- 54.6% vs 53.6% NCT02990806
- 59.4% vs 53.6% NCT02990806
- 57.3% vs 54.4% NCT02990806
- 60.9% vs 54.4% NCT02990806
- 52% vs 47.6% NCT02990806
- 57.9% vs 47.6% NCT02990806
- 56.4% vs 48.8% NCT02990806
- 59.4% vs 48.8% NCT02990806
- 61.7% vs 55.6% NCT02990806
- 61.4% vs 55.6% NCT02990806
- 62.1% vs 56.9% NCT02990806
- 61.4% vs 56.9% NCT02990806
- 55.5% vs 48.8% NCT02990806
- 57.9% vs 48.8% NCT02990806
- 58.1% vs 50% NCT02990806
- 57.4% vs 50% NCT02990806
- 62.6% vs 56.5% NCT02990806
- 61.9% vs 56.5% NCT02990806
- 60.8% vs 55.6% NCT02990806
- 62.4% vs 55.6% NCT02990806
- 56.8% vs 54.5% NCT02990806
- 55.9% vs 56.3% NCT02990806
- 62.6% vs 61.7% NCT02990806
- 62.6% vs 62.3% NCT02990806
- 56.4% vs 51.1% NCT02990806
- 56.8% vs 52.2% NCT02990806
- 47.1% vs 54.3% NCT02990806
- 46.7% vs 54.3% NCT02990806
- 31.3% vs 32.5% NCT02990806
- 29.1% vs 31.8% NCT02990806
- 56.7% vs 32.3% NCT01313520
ACR50
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- 30.8% vs 32.7%vs Remicade USNCT02990806
50 other results
- 28.4% vs 32.7% NCT02990806
- 29.1% vs 32.7% NCT02990806
- 27.9% vs 32.7% NCT02990806
- 32.6% vs 32.7% NCT02990806
- 34% vs 32.7% NCT02990806
- 32.6% vs 32.3% NCT02990806
- 33.5% vs 32.3% NCT02990806
- 36.6% vs 28.6% NCT02990806
- 32.5% vs 28.6% NCT02990806
- 36.1% vs 28.6% NCT02990806
- 29.4% vs 28.6% NCT02990806
- 37% vs 34.7% NCT02990806
- 35.5% vs 34.7% NCT02990806
- 34.8% vs 34.3% NCT02990806
- 34.5% vs 34.3% NCT02990806
- 30.8% vs 31.5% NCT02990806
- 30.5% vs 31.5% NCT02990806
- 29.5% vs 31.5% NCT02990806
- 29.4% vs 31.5% NCT02990806
- 33.5% vs 36.7% NCT02990806
- 40.6% vs 36.7% NCT02990806
- 33.5% vs 36.7% NCT02990806
- 37.1% vs 36.7% NCT02990806
- 31.3% vs 30.2% NCT02990806
- 34% vs 30.2% NCT02990806
- 32.2% vs 30.6% NCT02990806
- 32.5% vs 30.6% NCT02990806
- 35.2% vs 34.3% NCT02990806
- 39.1% vs 34.3% NCT02990806
- 35.2% vs 34.7% NCT02990806
- 39.1% vs 34.7% NCT02990806
- 30% vs 28.6% NCT02990806
- 29.4% vs 28.6% NCT02990806
- 29.1% vs 28.2% NCT02990806
- 28.4% vs 28.2% NCT02990806
- 34.4% vs 32.3% NCT02990806
- 31% vs 32.3% NCT02990806
- 33% vs 31.9% NCT02990806
- 30.5% vs 31.9% NCT02990806
- 27.8% vs 25.6% NCT02990806
- 27.8% vs 26.7% NCT02990806
- 32.2% vs 30.9% NCT02990806
- 31.7% vs 29.6% NCT02990806
- 24.7% vs 21.3% NCT02990806
- 23.3% vs 21.7% NCT02990806
- 16.3% vs 19.1% NCT02990806
- 14.5% vs 17.9% NCT02990806
- 8.4% vs 8.3% NCT02990806
- 6.6% vs 6.7% NCT02990806
- 20% vs 0% NCT01313520
ACR70
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- 17.2% vs 18.5%vs Remicade USNCT02990806
49 other results
- 13.2% vs 18.5% NCT02990806
- 16.3% vs 18.1% NCT02990806
- 15.2% vs 18.1% NCT02990806
- 18.9% vs 19.8% NCT02990806
- 16.2% vs 19.8% NCT02990806
- 17.2% vs 18.1% NCT02990806
- 14.7% vs 18.1% NCT02990806
- 18.1% vs 14.9% NCT02990806
- 15.7% vs 14.9% NCT02990806
- 17.2% vs 13.3% NCT02990806
- 13.7% vs 13.3% NCT02990806
- 22% vs 23% NCT02990806
- 18.3% vs 23% NCT02990806
- 20.7% vs 22.6% NCT02990806
- 15.7% vs 22.6% NCT02990806
- 15% vs 18.5% NCT02990806
- 14.7% vs 18.5% NCT02990806
- 15.4% vs 16.9% NCT02990806
- 13.2% vs 16.9% NCT02990806
- 17.2% vs 18.5% NCT02990806
- 18.3% vs 18.5% NCT02990806
- 14.5% vs 17.3% NCT02990806
- 15.7% vs 17.3% NCT02990806
- 17.6% vs 15.7% NCT02990806
- 14.7% vs 15.7% NCT02990806
- 16.3% vs 16.1% NCT02990806
- 14.2% vs 16.1% NCT02990806
- 18.1% vs 18.1% NCT02990806
- 20.8% vs 18.1% NCT02990806
- 16.7% vs 16.9% NCT02990806
- 19.3% vs 16.9% NCT02990806
- 16.3% vs 15.3% NCT02990806
- 13.2% vs 15.3% NCT02990806
- 15.4% vs 14.1% NCT02990806
- 11.7% vs 14.1% NCT02990806
- 16.3% vs 14.5% NCT02990806
- 13.2% vs 14.5% NCT02990806
- 15.4% vs 15.3% NCT02990806
- 12.7% vs 15.3% NCT02990806
- 10.6% vs 12.1% NCT02990806
- 11% vs 11.2% NCT02990806
- 15% vs 11.7% NCT02990806
- 14.5% vs 11% NCT02990806
- 11% vs 7.8% NCT02990806
- 9.7% vs 7.4% NCT02990806
- 6.6% vs 7.2% NCT02990806
- 5.7% vs 6.1% NCT02990806
- 0.9% vs 1.3% NCT02990806
- 0.9% vs 1.1% NCT02990806
DAS28-CRP remission
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- —Not posted · NCT01217086
HAQ-DI, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- -0.5 vs -0.5vs Remicade USNCT02990806
24 other results
- -0.4 vs -0.5 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.5 vs -0.6 NCT02990806
- -0.5 vs -0.6 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.4 vs -0.4 NCT02990806
- -0.4 vs -0.4 NCT02990806
- -0.3 vs -0.4 NCT02990806
- -0.4 vs -0.4 NCT02990806
- -0.3 vs -0.3 NCT02990806
- -0.3 vs -0.4 NCT02990806
- -0.2 vs -0.3 NCT02990806
Modified Sharp score, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab
- —Not posted · NCT01217086
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. adalimumab-aaty (Yuflyma): 5 of 5 rows · infliximab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-aaty (Yuflyma) | infliximab |
|---|---|---|
| DAS28-CRP absolute change · score | -2.945 vs -3.074 Humira score @ 52wka,b,c,d NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more dose-2.983 vs -3.074 Humira score @ 52wk NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | -2.466 vs -2.605 Remicade US score @ 62wka,b,c,d NCT02990806 · Phase 3 · registry result, not featured evidence show 1 more dose-2.404 vs -2.605 Remicade US score @ 62wk NCT02990806 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 6.5%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | —Infliximab + Methotrexate (Moderate NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 13 more results14.6%Infliximab + Methotrexate (Severe NCT00896168 · Phase 4 · registry result, not featured evidence · combination —Stage 1, 2 and 3: NI-071 Group NCT02990806 · Phase 3 · registry result, not featured evidence —Stage 2 and Stage 3: Remicade US t NCT02990806 · Phase 3 · registry result, not featured evidence 38% NCT00732875 · Phase 3 · registry result, not featured evidence · combination —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 6.1%Open-label NCT00691028 · Phase 3 · registry result, not featured evidence 0% NCT01313520 · Phase 2 · registry result, not featured evidence 10% NCT00948610 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 2.2%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | —Infliximab + Methotrexate (Moderate NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 13 more results5.4%Infliximab + Methotrexate (Severe NCT00896168 · Phase 4 · registry result, not featured evidence · combination —Stage 1, 2 and 3: NI-071 Group NCT02990806 · Phase 3 · registry result, not featured evidence —Stage 2 and Stage 3: Remicade US t NCT02990806 · Phase 3 · registry result, not featured evidence 17.4% NCT00732875 · Phase 3 · registry result, not featured evidence · combination —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 4.9%Open-label NCT00691028 · Phase 3 · registry result, not featured evidence — NCT01313520 · Phase 2 · registry result, not featured evidence — NCT00948610 · Phase na · registry result, not featured evidence |
| Serious AEs | —CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.7%Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 2%Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.3%Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | 1.9%Infliximab + Methotrexate (Moderate NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 13 more results1.5%Infliximab + Methotrexate (Severe NCT00896168 · Phase 4 · registry result, not featured evidence · combination 8.4%Stage 1, 2 and 3: NI-071 Group NCT02990806 · Phase 3 · registry result, not featured evidence 6.6%Stage 2 and Stage 3: Remicade US t NCT02990806 · Phase 3 · registry result, not featured evidence 13% NCT00732875 · Phase 3 · registry result, not featured evidence · combination —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 8.7%10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 4.8%6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 7.1%3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 5.2%Open-label NCT00691028 · Phase 3 · registry result, not featured evidence 0% NCT01313520 · Phase 2 · registry result, not featured evidence 0% NCT00948610 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | upper respiratory tract infection 5.6% nasopharyngitis 5.2% injection site reaction 4.9% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 show 2 more resultsneutropenia 5% upper respiratory tract infection 3.3% urinary tract infection 3% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 neutropenia 5.3% alanine aminotransferase increased 4.6% leukopenia 4.6% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | e hepatic function disnormal 50% upper respiratory infection 27.9% fever 3.8% NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 9 more resultshepatic function disnormal 37.7% upper respiratory infection 30% hypolekocytosis 10.8% NCT00896168 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 12.3% upper respiratory tract infection 10.6% headache 7% NCT02990806 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.7% upper respiratory tract infection 10.2% alanine aminotransferase increased 6.6% NCT02990806 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 20.7% pruritus 12% urticaria 9.8% NCT00732875 · Phase 3 · registry result, not featured evidence · combination 10 mg/kg dna antibody positive 51.9% nasopharyngitis 28.8% antinuclear antibody positive 16.3% NCT00691028 · Phase 3 · registry result, not featured evidence 6 mg/kg dna antibody positive 55.8% nasopharyngitis 27.9% antinuclear antibody positive 14.4% NCT00691028 · Phase 3 · registry result, not featured evidence 3 mg/kg dna antibody positive 65.7% nasopharyngitis 29.3% antinuclear antibody positive 25.3% NCT00691028 · Phase 3 · registry result, not featured evidence nasopharyngitis 17.1% alanine aminotransferase increased 10.1% aspartate aminotransferase increased 6.1% NCT00691028 · Phase 3 · registry result, not featured evidence joint swelling 13.3% (placebo 19.4%) headache 6.7% (placebo 0%) palpitations 6.7% (placebo 0%) NCT01313520 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 62 weeks versus 52 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
infliximab
show 1 more result
show 6 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aaty (Yuflyma)'s landscape · infliximab's landscape